Development of Antibodies to Ustekinumab Is Associated with Loss of Response in Patients with Inflammatory Bowel Disease

Monitoring of anti-drug antibodies in patients on ustekinumab is not routinely recommended in patients with inflammatory bowel disease (IBD) due to low rates of immunogenicity. Aim of study: The purpose of this study was to investigate the relationship between anti-drug antibodies detected by a drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Roblin, Xavier, Duru, Gérard, Papamichael, Konstantinos, Cheifetz, Adam S., Kwiatek, Sandy, Berger, Anne-Emmanuelle, Barrau, Mathilde, Waeckel, Louis, Nancey, Stephane, Paul, Stephane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219534/
https://www.ncbi.nlm.nih.gov/pubmed/37240501
http://dx.doi.org/10.3390/jcm12103395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219534/
https://www.ncbi.nlm.nih.gov/pubmed/37240501
http://dx.doi.org/10.3390/jcm12103395

Ejemplares similares